Drug targets of migraine and neuropathy

Treatment of hyperexcitability

L. Vécsei, Zsófia Majláth, Anna Balog, J. Tajti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.

Original languageEnglish
Pages (from-to)664-676
Number of pages13
JournalCNS and Neurological Disorders - Drug Targets
Volume14
Issue number5
Publication statusPublished - Jun 1 2015

Fingerprint

Neuralgia
Migraine Disorders
Pharmaceutical Preparations
Central Nervous System Sensitization
Trigeminal Nuclei
Kynurenine
Posterior Horn Cells
Trigeminal Ganglion
Hyperalgesia
Glutamate Receptors
Spinal Ganglia
N-Methyl-D-Aspartate Receptors
Synaptic Transmission
Chronic Pain
Anticonvulsants
Therapeutics
Drug Therapy
Skin

Keywords

  • Allodynia
  • Glutamate
  • Hyperexcitability
  • Migraine
  • Neuropathic pain
  • Sensitization

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Drug targets of migraine and neuropathy : Treatment of hyperexcitability. / Vécsei, L.; Majláth, Zsófia; Balog, Anna; Tajti, J.

In: CNS and Neurological Disorders - Drug Targets, Vol. 14, No. 5, 01.06.2015, p. 664-676.

Research output: Contribution to journalArticle

@article{b8ebe59c046f4ca6b1cc4fec5669b9cd,
title = "Drug targets of migraine and neuropathy: Treatment of hyperexcitability",
abstract = "Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.",
keywords = "Allodynia, Glutamate, Hyperexcitability, Migraine, Neuropathic pain, Sensitization",
author = "L. V{\'e}csei and Zs{\'o}fia Majl{\'a}th and Anna Balog and J. Tajti",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "14",
pages = "664--676",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Drug targets of migraine and neuropathy

T2 - Treatment of hyperexcitability

AU - Vécsei, L.

AU - Majláth, Zsófia

AU - Balog, Anna

AU - Tajti, J.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.

AB - Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.

KW - Allodynia

KW - Glutamate

KW - Hyperexcitability

KW - Migraine

KW - Neuropathic pain

KW - Sensitization

UR - http://www.scopus.com/inward/record.url?scp=84930516185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930516185&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 664

EP - 676

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 5

ER -